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A B S T R A C T
Background and purpose: Stopping-power ratios (SPRs) are used in particle therapy to calculate particle range in
patients. The heuristic CT-to-SPR conversion (Hounsﬁeld Look-Up-Table, HLUT), needed for treatment planning,
depends on CT-scan and reconstruction parameters as well as the speciﬁc HLUT deﬁnition. To assess inter-centre
diﬀerences in these parameters, we performed a survey-based qualitative evaluation, as a ﬁrst step towards
better standardisation of CT-based SPR derivation.
Materials and methods: A questionnaire was sent to twelve particle therapy centres (ten from Europe and two
from USA). It asked for details on CT scanners, image acquisition and reconstruction, deﬁnition of the HLUT,
body-region speciﬁc HLUT selection, investigations of beam-hardening and experimental validations of the
HLUT. Technological improvements were rated regarding their potential to improve SPR accuracy.
Results: Scan parameters and HLUT deﬁnition varied widely. Either the stoichiometric method (eight centres) or
a tissue-substitute-only HLUT deﬁnition (three centres) was used. One centre combined both methods. The
number of HLUT line segments varied widely between two and eleven. Nine centres had investigated inﬂuence of
beam-hardening, often including patient-size dependence. Ten centres had validated their HLUT experimentally,
with very diﬀerent validation schemes. Most centres deemed dual-energy CT promising for improving SPR ac-
curacy.
Conclusions: Large inter-centre variability was found in implementation of CT scans, image reconstruction and
especially in speciﬁcation of the CT-to-SPR conversion. A future standardisation would reduce time-intensive
institution-speciﬁc eﬀorts and variations in treatment quality. Due to the interdependency of multiple para-
meters, no conclusion can be drawn on the derived SPR accuracy and its inter-centre variability.
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1. Introduction
The heuristic conversion from CT number to particle stopping-
power ratio (SPR) is one of the main contributions to uncertainties in
treatment planning of particle therapy [1,2]. The conversion between
CT number and SPR is usually performed by applying a piecewise linear
function, referred to as a Hounsﬁeld Look-Up-Table (HLUT).
In general, two diﬀerent approaches exist for HLUT generation,
“tissue-substitute-only” [3] and “stoichiometric” HLUT deﬁnition [4].
In the ﬁrst case, only measured CT numbers and SPR from tissue-mi-
micking materials are used, whereas in stoichiometric approach the CT
number and SPRs are predicted for diﬀerent (biological) tissues of
known tissue composition. The CT number prediction is speciﬁc for the
used scan settings and requires a calibration, again with tissue sub-
stitutes.
As photon attenuation is dependent on photon energy, the CT
number for a speciﬁc tissue will depend on the X-ray energy spectrum
and detector response of the CT scanner, as well as the reconstruction
parameters. Furthermore, beam-hardening will lead to CT number
variations, especially for high-density materials, depending on the
surrounding material and the size of the entire scanned object [5]. An
improved CT number constancy can be obtained by applying re-
construction algorithms with sophisticated beam-hardening correction
(BHC) that distinguishes between bone- and water-like contents.
Hence, a multitude of parameters inﬂuence the CT-to-SPR conver-
sion: (a) CT scan parameters (e.g. energy spectrum, energy ﬁlters, type
of detector); (b) reconstruction parameters (reconstruction kernel, in-
cluding BHC, and image smoothing); (c) HLUT deﬁnition details. This
leads to a cumbersome, work intense and error-prone process, which
each particle centre currently must perform individually for their spe-
ciﬁc hardware (CT scanner) and software settings. This process consists
of the following steps: [1] Deﬁnition of CT scan and reconstruction
protocol, ideally after its optimisation regarding image noise and con-
trast as well as CT number constancy for diﬀerent body regions
(minimising remaining beam-hardening eﬀects); [2] HLUT deﬁnition
for this CT protocol; [3] Validation of the HLUT in a realistic scenario.
Currently, 68 new particle facilities are in planning or construction
phase [6]. Hence, missing standardisation in CT-to-SPR conversion and
resulting inter-centre diﬀerences as well as limited accuracy in range
prediction, already today a problem for centres in operation [7], are
becoming even more of an issue in the near future.
To assess the inter-centre variability of CT image acquisition and
reconstruction as well as calibration and validation of HLUT-based CT-
to-SPR conversion, a survey-based qualitative evaluation was carried
out in the framework of the European Particle Therapy Network
(EPTN). Aiming to access the current status of inter-centre diﬀerences,
this investigation was intended as a ﬁrst step towards better standar-
disation of CT-based SPR derivation.
2. Material and methods
A questionnaire was sent to ten currently operational particle
therapy centres connected to the EPTN, an ESTRO task group, and two
operational centres in the US in the period from 1st of December 2016
to 1st of February 2017. The questionnaire concerned the conversion of
CT numbers in treatment planning CT datasets to SPRs used for dose
and range calculations in particle therapy. It mainly focused on (a)
details on CT scanners, acquisition and reconstruction parameters, (b)
HLUT deﬁnition, (c) HLUT validation, (d) body-region speciﬁc HLUT
selection, (e) artifact handling and, (f) quality assurance (see
Supplementary data).
As the HLUT depends on the speciﬁc scan and reconstruction
parameters, a direct comparison of the diﬀerent HLUTs and their re-
spective SPR accuracy was not possible per deﬁnition. The ques-
tionnaire therefore focused on how the HLUT had been designed and
how beam-hardening was handled.
The centres were also asked if they intended to change their current
calibration method in the near future and their views on how the ac-
curacy of treatment planning could be improved. Further, ﬁve up-
coming innovations and technological improvements, currently under
strong investigation were rated from 1 (most important) to 6 (least
important) regarding their potential to improve range prediction ac-
curacy. These ﬁve suggestions were dual-energy CT (DECT), proton CT,
photon-counting-detector CT (PCD-CT), better calibration methods, and
Monte Carlo based dose calculation.
3. Results
3.1. Facility speciﬁcations
Most of the centres participating in this survey had recently started
clinical operation. The median operational time was three years. The
most experienced centre had been treating patients since 1991. This
centre implemented their current HLUT in 2001. Only one other centre
had been in operation for more than ten years. One centre was not yet
in operation at the time of answering the questionnaire, but has in the
meantime started treating patients.
All centres had the ability to treat with pencil beam scanning (PBS);
however, ﬁve centres also used passive double-scattering (DS). The
following treatment planning systems (TPSs) were used: Eclipse (Varian
Medical Systems, Palo Alto, CA, USA; six centres), RayStation
(RaySearch Laboratories, Stockholm, Sweden; four centres) and Syngo
RT Planning (Siemens Healthineers, Forchheim, Germany; two centres).
Two centres using RayStation also used XiO (Elekta, Stockholm,
Sweden).
All centres treated tumours situated in the brain, the head-and-neck
region, and the pelvis area (Fig. 1). Other common treatment sites were
abdomen (nine centres), thorax (eight), and extremities (seven). Less
common treatment sites were ocular tumours (ﬁve), and breast tumours
(three).
A relative range uncertainty margin (RUM) of 3.5% of the total
particle range was applied by seven institutions. An additional absolute
RUM of 2mm or 1mm was used by two and one centre, respectively.
One centre chose the additional margin based on the delivery tech-
nique, 1 mm for PBS plans and 3mm for DS plans. Another centre, also
using a relative RUM of 3.5%, increased their RUM in some cases, e.g.
for cranio-spinal irradiations. A relative RUM of 3% was used by a
Fig. 1. Anatomical sites treated at the diﬀerent particle therapy centres. The
category “Other” includes cranio-spinal treatments and irradiations close to the
spine.
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single centre, but this was increased to 5% when large uncertainties
were foreseen, e.g. due to hardware, CT number uncertainty, or exact
tumour location. Three institutions only used ﬁxed RUMs, ranging from
2 to 7mm. Here, diﬀerent RUMs were used for diﬀerent treatment si-
tuations, e.g. one centre used smaller margins (4 mm) for children
compared to adults (5–7mm).
3.2. CT scanner speciﬁcation
Most centres had a CT scanner from either Siemens Healthineers
(nine centres) or Philips (Philips Healthcare, Cleveland, OH, USA) (four
centres). A GE (General Electric, Fairﬁeld, CT, USA) and a Toshiba CT
scanner (Toshiba Medical Systems, Ohtawara, Japan) were available at
one institution each. A few CT scanners were integrated PET/CT
scanners (Table 1).
Six centres were equipped with a scanner with DECT capabilities
(Siemens Deﬁnition AS). However, only one centre used the DECT
capability for a subgroup of their patients (brain and pelvic region). For
body regions with potential body and/or organ motion, single-energy
CT (SECT) was applied at this institution. All other centres exclusively
used SECT for treatment planning. Treatment planning on contrast-
enhanced CT datasets was not performed at any participating institu-
tion.
For SECT scans, a tube potential of 120 kVp was used by all parti-
cipating institutions. In addition, four centres applied diﬀerent tube
potentials between 80 and 140 kVp depending on the patient group
(Table 1).
The CT datasets were reconstructed using Filtered Back-Projection
(FBP) in eight centres, while three institutions applied iterative re-
constructions; one centre applied either FBP or iterative reconstruction
based on the speciﬁc scanner used. One centre used a reconstruction
protocol with bone-BHC for all patients, while four other centres lim-
ited the bone-BHC to head-and-neck cases and applied a water-BHC for
all other cases. The remaining seven centres used water-BHC in all si-
tuations.
3.3. Inﬂuence of beam-hardening
Nine centres had examined the impact of setup variations on CT
number stability, while the three other centres had not investigated the
inﬂuence of beam-hardening. The most commonly performed test was
to acquire CT scans of tissue substitutes placed in phantoms of diﬀerent
sizes. Two centres had investigated the inﬂuence of diﬀerent positions
of the tissue substitutes within the ﬁeld-of-view (FOV). Other in-
vestigated parameters included tube potential (kVp), tube current-time
product (mAs), detector settings, pitch, rotation time, reconstruction
algorithm, slice thickness, and FOV.
3.4. HLUT deﬁnition
All centres applied an in-house deﬁned HLUT. For one planning
system (RayStation), the conversion from CT number to mass density
needed to be speciﬁed, as a hardcoded conversion from mass density to
particle SPR is applied internally using so-called core-materials.
The stoichiometric and tissue-substitute-only method was used by
eight and three centres, respectively. One institution applied a combi-
nation of the stoichiometric method and experimental SPR measure-
ments of tissue substitutes (Table 2). All centres used either inserts from
CIRS (Norfolk, VA, USA) or Gammex (Middleton, WI, USA) for either
the scanner-speciﬁc calibration of the stoichiometric or for their tissue-
substitute-only calibration. It should be noted that mostly standardised
electron density phantoms including the respective tissue surrogate
inserts were chosen that are optimised for tissue-equivalence for pho-
tons, in contrast to other available tissue substitute materials optimised
for proton-tissue-equivalence.
The HLUTs were deﬁned by two to eleven linear line segments, ei-
ther based on linear interpolation between data points or on step-wise
linear ﬁts for diﬀerent CT number regions. For one institution, the in-
dividual linear ﬁts were connected using connecting lines, while three
centres joined the linear ﬁts in the intersection of the two adjacent ﬁts.
A single centre, using a stoichiometric curve with three linear segments,
placed their two intersection points at speciﬁc reference human tissue
data points. Two centres forced their conversion curve through the data
point for water.
Table 1
CT scanner speciﬁcation used at the twelve diﬀerent institutions. Abbreviations: BHC: Beam-hardening correction; FBP: Filtered back-projection. 2 ×/4 ×: Two/four
CT scanners of the same model.
Institution number Scanner model Scan and reconstruction protocol
Tube potential (kVp) Reconstruction
Type Type of BHC
1 Siemens Sensation Open 120, 140 FBP Bone-BHC for head
Water-BHC for abdomen
2 Philips Brilliance Big Bore 120 FBP Water-BHC
3 Philips Brilliance Big Bore 120, 140 FBP Water-BHC
4 i. Toshiba Aquilion LB
ii. Siemens Deﬁnition AS
iii. Siemens Sensation Open
iv. GE LightSpeed RT16









ii. Bone-BHC for head/Water-BHC for abdomen
iii. Bone-BHC for head/Water-BHC for abdomen
iv. Water-BHC
5 Siemens Deﬁnition AS 120 FBP Water-BHC
6 i. Siemens Sensation Open
ii. Siemens Deﬁnition – part of PET/CT Biograph40
iii. Siemens Conﬁdence
iv. Siemens Sensation Open
120 FBP Bone-BHC for head
Water-BHC for abdomen
7 Siemens Deﬁnition AS 120 FBP Water-BHC
8 4 × Siemens Deﬁnition AS 120 Iterative Water-BHC
9 Siemens Sensation 120 FBP Water-BHC
10 i. Siemens Sensation Open
ii. Philips TF Big Bore PET-CT
120 FBP Water-BHC
11 2 × Siemens Deﬁnition AS SECT: 120
DECT: 80/140
Iterative Bone-BHC
12 Siemens Deﬁnition AS 120 for adults
80 for children
Iterative Not provided
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HLUT re-assessment was performed yearly in four institutions.
Other centres only checked for CT number stability. From the provided
feedback, re-calibration seems to be necessary only very seldom. Two
centres would check their HLUT after CT scanner repair and main-
tenance.
3.4.1. Multiple HLUTs
As beam-hardening can cause CT numbers to diﬀer depending on
the size of the object being scanned, it was assessed whether the same
HLUT was applied for all anatomical sites or diﬀerent HLUTs were used.
Between one and six diﬀerent HLUTs were applied. A common strategy
was to have two diﬀerent calibration curves allowing for a diﬀer-
entiation between head and abdomen. Five institutions also applied a
dedicated HLUT for large and/or paediatric patients. E.g. one institu-
tion had three diﬀerent HLUTs for children, diﬀerentiating between
head, pelvis, and infants. Five institutions used a single HLUT for all
treatment sites. One of them had minimised the inﬂuence of beam-
hardening by using bone-BHC in all scans and veriﬁed the applicability
of a single HLUT.
In centres with multiple CT scanners, either the same HLUT was
used (two centres with the same CT scanner model and one centre with
CT scanners from diﬀerent vendors) or individual scanner-speciﬁc
HLUTs were applied (four centres).
3.4.2. Experimental HLUT validation
All but two institutions had experimentally validated their CT-to-
SPR conversion. The validation usually was performed with water-
equivalent thickness (WET) measurements for tissue-substitute mate-
rials (six centres) and/or animal tissues (seven centres). One institution
had also measured the WET for two beam paths through a human ca-
daver, resulting in a slight adjustment of their original HLUT eﬀecting
adipose tissue (Table 2).
3.5. Metal artifacts
For the assessment of metal artifacts, eight centres contoured the
aﬀected region and manually assigned the appropriate CT number, SPR
or mass density. One institution assigned all metals to titanium. Three
centres used metal artifact reduction (MAR) reconstruction algorithms.
One of them applied it for all treatment planning scans.
Four institutions reported that they tried to avoid beam directions
through metals and streak artifacts, one centre speciﬁed that they
especially avoided beam directions parallel to streak artifacts. Another
centre reported that patients would be referred to photon therapy if CT
image quality was not suﬃcient due to metal artifacts in the beam path.
This is probably the case in other centres too.
3.6. Future improvements
3.6.1. Planned changes
Seven of twelve institutions had speciﬁc plans for changing/up-
dating their calibration process. For six of them, these updates included
the use of DECT, though to varying degree. Some of these centres were
awaiting results for validation of DECT-based range prediction in or-
ganic tissues and quantiﬁcation of its gain in accuracy. One centre
speciﬁcally wanted to use DECT to reconstruct pseudo-monoenergetic
datasets similar to Ref. [5]. Other intended changes were the use of
multiple HLUTs depending on the patient size, use of additional high-
density tissue substitutes for HLUT deﬁnition, and implementation of
bone-BHC. One centre intended to shift from a tissue-substitute-only to
the stoichiometric approach.
3.6.2. Suggestions for further improvement
When the centres were asked to score given upcoming techniques
regarding their potential to improve range prediction accuracy, a large
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better dose calculation algorithms (including Monte Carlo dose calcu-
lations) were scored relatively high by all institutions. Other ideas,
provided in free-form comments, included optimisation of CT protocols
concerning image noise and beam-hardening, robust optimisation and
adaptive therapy. In-vivo range veriﬁcation was also suggested by ﬁve
centres, including prompt-gamma, PET and proton range probes. One
institution intended to investigate patient-speciﬁc HLUT adaptations.
For one centre, it was important to deal with the largest sources of
errors ﬁrst, which they considered to be anatomical changes in the
patient, therefore their most important improvement would be to
change to an adaptive regime, with regular, maybe even daily, adap-
tations.
4. Discussion
The current status of CT-to-SPR conversion for particle treatment
planning was assessed for twelve centres. Although mostly 120 kVp CT
scans were used, a large inter-centre variability in implementation of
CT scans, image reconstruction and especially in CT-to-SPR conversion
was found. All participating institutions applied a heuristic HLUT which
can therefore be seen as current gold standard.
This is in line with a previously performed HLUT inter-comparison
at proton centres in USA [7], where large deviations were also found
between the centre-speciﬁc conversion curves and a study-speciﬁc re-
ference HLUT. However, also this study was unable to provide con-
clusions on SPR accuracy [7].
This study was not only helpful to derive the status-quo in CT-based
SPR determination, but it could also be of immediate interest for par-
ticle centres in the start-up phase. Many particle therapy centres will
have to deﬁne their HLUT in the near future. Currently, 42 proton and
four carbon-ion centres are under construction and 22 proton facilities
are in the planning phase [6]. From this fact and the large variability in
CT-based SPR prediction found in this study, the beneﬁt of a future
standardisation of is obvious: It would reduce time-intensive
institution-speciﬁc eﬀorts. More important, harmonised SPR prediction
would reduce variations in treatment quality, which would be of beneﬁt
when conducting multi-centric clinical trials. Hence, standardisation is
highly demanded in particle therapy. It would be beneﬁcial, if in-
dividual particle therapy centres, leading organisations as PTCOG,
AAPM, ESTRO as well as CT manufacturers and TPS providers would
put their eﬀorts together to work towards this goal. Of course, such
standardisation is not trivial, not only due to the dependence on CT
scanner hardware. Nevertheless, CT manufacturers could provide scan
and reconstruction protocols optimised for the demands in particle
therapy (e.g. minimising remaining beam-hardening) and the particle
therapy community could formulate a recommendation for HLUT-based
CT-to-SPR conversion.
The majority of the participating institutions had addressed beam-
hardening, either by using diﬀerent HLUTs for diﬀerent body regions
(e.g. head and abdomen region) or by using sophisticated BHC. On the
other hand, not all institutions with a single one-ﬁts-it-all HLUT had
investigated the size dependency. As a recommendation, the inﬂuence
of beam-hardening should be quantiﬁed and addressed, especially for
particle therapy centres relying on a single HLUT. If no bone-BHC is
applied, the use of dedicated HLUT for speciﬁc body regions should be
considered. Most centres had performed an experimental validation of
their HLUT (Table 2), see Refs. [8–12].
In the near future, most participating centres expect a beneﬁt for
SPR prediction from DECT. However, only one institution has im-
plemented DECT scans for clinical treatment planning, still applying a
HLUT based on pseudo-monoenergetic CT datasets. No centre has so far
implemented direct, patient-speciﬁc DECT-based SPR prediction.
However, from recent investigations the evidence concerning the ben-
eﬁt of DECT for more accurate and patient-speciﬁc SPR prediction is
growing [10,13–22]. The additional information derived from DECT-
based SPR prediction can be used to either adapt the heuristic HLUT or
to directly use it for fully patient-speciﬁc SPR prediction. Particle
therapy centres that are currently in the phase of CT scanner procure-
ment should consider having a DECT option available. Moreover, a
large fraction of the participating institutions deemed proton CT and
PCD-CT as of intermediate importance, even though no substantial
experimental evidence for a clinically realistic scenario has yet been
proven for either of these techniques. The use of proton radiography or
range probe measurements [12,23] seems to be a pragmatic and pro-
mising alternative research avenue.
A limitation of this study was that only two centres outside Europe
participated. Furthermore, several questions were in free-form format,
which made it diﬃcult to compare answers in those cases. Other
questions were in multiple-choice format with only a few response
options which potentially could limit the responses even though most of
these questions were supplied with a text ﬁeld for other answers. A
principle limitation of the study is its qualitative nature, which for
example did not allow a quantiﬁcation of range prediction accuracy and
its inter-centre variability. Note that diﬀerent calibration curves for
diﬀerent CT hardware as well as scan and reconstruction settings can
result in the same SPR prediction and (more importantly) vice versa.
Therefore, a dedicated inter-centre comparison of SPR prediction ac-
curacy will be performed using a ground-truth phantom and applying
the institution-speciﬁc hardware- and software solutions in an end-to-
end-test-scenario as a next step within the EPTN.
A large inter-centre variability in implementation of CT scans,
image reconstruction and especially in HLUT deﬁnition was found in
this survey-based study. It reveals that no standard procedures exist in
terms of scan- and reconstruction-parameter optimisation, mitigation of
beam-hardening artefacts and HLUT deﬁnition. All these issues are of
importance and should be addressed with care by each particle therapy
centre. Hence, a standardisation of CT-based SPR prediction is highly
recommended.
Fig. 2. Scored importance for SPR calculation in proton treatment planning.
Importance score deﬁnition: 1: most important, 6: least important – more
techniques could be scored equally. The median is shown by the red lines, and
the blue boxes extend from the 25% to the 75% percentile. Abbreviation: NA:
No answer. (For interpretation of the references to colour in this ﬁgure legend,
the reader is referred to the web version of this article.)
V.T. Taasti et al. Physics and Imaging in Radiation Oncology 6 (2018) 25–30
29
Disclosure of conﬂicts of interest
The institution of CR and PW has an institutional research agree-
ment with Siemens Healthineers in place. The authors have no further
conﬂicts of interest to disclose.
Acknowledgement
The authors would like to thank all participating centres for pro-
viding valuable information.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in the
online version, at http://dx.doi.org/10.1016/j.phro.2018.04.006.
References
[1] Yang M, Zhu XR, Park PC, Titt U, Mohan R. Comprehensive analysis of proton range
uncertainties related to patient stopping-power-ratio estimation using the stoi-
chiometric calibration. Phys Med Biol 2012;57:4095–115.
[2] Paganetti H. Range uncertainties in proton therapy and the role of Monte Carlo
simulations. Phys Med Biol 2012;57:R99–117.
[3] Jäkel O, Jacob C, Schardt D, Karger CP, Hartmann GH. Relation between carbon ion
ranges and x-ray CT numbers. Med Phys 2001;28(4):701–3.
[4] Schneider U, Pedroni E, Lomax A. The calibration of CT Hounsﬁeld units for
radiotherapy treatment planning. Phys Med Biol 1996;41(1):111–24.
[5] Wohlfahrt P, Möhler C, Hietschold V, Menkel S, Greilich S, Krause M, et al. Clinical
implementation of dual-energy CT for proton treatment planning on pseudo-
monoenergetic CT scans. Int J Radiat Oncol Biol Phys 2017;97(2):427–34.
[6] Particle Therapy Co-Operative Group (PTCOG). Particle Therapy Centers [Internet].
2017 [cited 2018 Feb 11]. Available from: www.ptcog.ch.
[7] Moyers MF. Comparison of X ray computed tomography number to proton relative
linear stopping power conversion functions using a standard phantom. Med Phys
2014;41(6):61705.
[8] Schaﬀner B, Pedroni E. The precision of proton range calculations in proton
radiotherapy treatment planning: experimental veriﬁcation of the relation between
CT-HU and proton stopping power. Phys Med Biol 1998;43(6):1579–92.
[9] Qamhiyeh S. A Monte Carlo study of the accuracy of CT-numbers for range calcu-
lations in Carbon ion therapy [Internet]. Ruperto-Carola University of Heidelberg;
2007 Available from: http://archiv.ub.uni-heidelberg.de/volltextserver/7378/1/
Qamhiyeh_PhD_thesis.pdf.
[10] Hünemohr N, Krauss B, Dinkel J, Gillmann C, Ackermann B, Jäkel O, et al. Ion range
estimation by using dual energy computed tomography. Z Med Phys
2013;23(4):300–13.
[11] Telsemeyer J, Ackermann B, Ecker S, Jäkel O, Martišíková M. Experimental ver-
iﬁcation of ion range calculation in a treatment planning system using a ﬂat-panel
detector. Phys Med Biol 2014;59(14):3737–47.
[12] Farace P, Righetto R, Meijers A. Pencil beam proton radiography using a multilayer
ionization chamber. Phys Med Biol 2016;61(11):4078–87.
[13] Bourque AE, Carrier J-F, Bouchard H. A stoichiometric calibration method for dual
energy computed tomography A stoichiometric calibration method for dual energy
computed tomography. Phys Med Biol 2014;59:2059–89.
[14] Hansen DC, Seco J, Sørensen TS, Breede JBB, Petersen B, Wildberger JE, et al. A
simulation study on proton computed tomography (CT) stopping power accuracy
using dual energy CT scans as benchmark. Acta Oncol 2015;54:1638–42.
[15] Hudobivnik N, Schwarz F, Johnson T, Agolli L, Dedes G, Tessonnier T, et al.
Comparison of proton therapy treatment planning for head tumors with a pencil
beam algorithm on dual and single energy CT images. Med Phys
2016;43(1):495–504.
[16] Bär E, Lalonde A, Royle G, Lu H-M, Bouchard H. The potential of dual-energy CT to
reduce proton beam range uncertainties. Med Phys 2017;44(6):2332–44.
[17] Li B, Lee HC, Duan X, Shen C, Zhou L, Jia X, et al. Comprehensive analysis of proton
range uncertainties related to stopping-power-ratio estimation using dual-energy
CT imaging. Phys Med Biol 2017;62(17):7056–74.
[18] Wohlfahrt P, Möhler C, Richter C, Greilich S. Evaluation of stopping-power pre-
diction by dual- and single-energy computed tomography in an anthropomorphic
ground-truth phantom. Int J Radiat Oncol Biol Phys 2017;100(1):244–53.
[19] Wohlfahrt P, Möhler C, Stützer K, Greilich S, Richter C. Dual-energy CT based
proton range prediction in head and pelvic tumor patients. Radiother Oncol
2017;125(3):526–33.
[20] Taasti VT, Michalak GJ, Hansen DC, Deisher A, Kruse JJ, Krauss B, et al. Validation
of proton stopping power ratio estimation based on dual energy CT using fresh
tissue samples. Phys Med Biol 2018;63:15012.
[21] Bär E, Lalonde A, Zhang R, Jee K-W, Yang K, Sharp G, et al. Experimental validation
of two dual-energy CT methods for proton therapy using heterogeneous tissue
samples. Med Phys 2018;45(1):48–59.
[22] Möhler C, Russ T, Wohlfahrt P, Elter A, Runz A, Richter C, et al. Experimental
veriﬁcation of stopping-power prediction from single- and dual-energy computed
tomography in biological tissues. Phys Med Biol 2018;63:25001.
[23] Farace P, Righetto R, Deﬀet S, Meijers A, Vander Stappen F. Technical Note: A
direct ray-tracing method to compute integral depth dose in pencil beam proton
radiography with a multilayer ionization chamber. Med Phys
2016;43(12):6405–12.
[24] Woodard HQ, White DR. The composition of body tissues. Br J Radiol
1986;59:1209–18.
[25] White DR, Woodard HQ, Hammond SM. Average soft tissue and bone models. Br J
Radiol 1987;60:907–13.
[26] International Commission on Radiation Units and Measurements (ICRU). Tissue
Substitutes in Radiation Dosimetry and Measurement (Report 44). Bethesda, MD;
1989.
[27] International Commission on Radiological Protection (ICRP). Report of the Task
Group on Reference Man ICRP Publication 23 New York: Pergamon Press; 1974.
V.T. Taasti et al. Physics and Imaging in Radiation Oncology 6 (2018) 25–30
30
